La bourse ferme dans 5 h 24 min
  • CAC 40

    5 913,66
    +10,67 (+0,18 %)
     
  • Euro Stoxx 50

    3 778,81
    +15,57 (+0,41 %)
     
  • Dow Jones

    31 802,44
    +306,14 (+0,97 %)
     
  • EUR/USD

    1,1908
    +0,0055 (+0,46 %)
     
  • Gold future

    1 700,60
    +22,60 (+1,35 %)
     
  • BTC-EUR

    45 507,98
    +3 267,89 (+7,74 %)
     
  • CMC Crypto 200

    1 093,92
    +69,71 (+6,81 %)
     
  • Pétrole WTI

    65,67
    +0,62 (+0,95 %)
     
  • DAX

    14 435,72
    +54,81 (+0,38 %)
     
  • FTSE 100

    6 749,44
    +30,31 (+0,45 %)
     
  • Nasdaq

    12 609,16
    -310,99 (-2,41 %)
     
  • S&P 500

    3 821,35
    -20,59 (-0,54 %)
     
  • Nikkei 225

    29 027,94
    +284,69 (+0,99 %)
     
  • HANG SENG

    28 773,23
    +232,40 (+0,81 %)
     
  • GBP/USD

    1,3880
    +0,0059 (+0,42 %)
     

Biophytis Announces Plan to Publicly File Later Today Registration Statement for Proposed Initial Public Offering in the United States

BIOPHYTIS SA
·4 min de lecture

PARIS and CAMBRIDGE, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19, today announces that it plans to publicly file a registration statement on Form F-1 with the U.S. Securities and Exchange Commission (the “SEC”) today in relation to a proposed initial public offering of ordinary shares in the form of American Depositary Shares (the “ADSs”) in the United States (the “ADS Offering”) and proposed Nasdaq listing in connection therewith. All securities to be sold in the ADS Offering will be offered by Biophytis. The number of securities, including the ratio of ordinary shares to ADS, and the price range of the securities to be sold in the ADS Offering have not yet been determined.

About Biophytis
Biophytis SA is a clinical-stage biotechnology company specialized in the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19.

The company is based in Paris, France, and Cambridge, Massachusetts. The company's common shares are listed on the Euronext Growth Paris market (Ticker: ALBPS -ISIN: FR0012816825).

Disclaimer
This press release contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. In some cases, you can identify these forward-looking statements by the use of words such as "outlook," "believes," "expects," "potential," "continues," "may," "will," "should," "could," "seeks," "predicts," "intends," "trends," "plans," "estimates," "anticipates" or the negative version of these words or other comparable words. These forward-looking statements include certain statements regarding Biophytis’ proposed initial public offering as well as its business, including its prospects and product development. Such forward-looking statements are based on assumptions that Biophytis considers to be reasonable. However, there can be no assurance that the statements contained in such forward-looking statements will be verified, which are subject to various risks and uncertainties including, without limitation, risks inherent in the development and/or commercialization of potential products, the outcome of its studies, uncertainty in the results of pre-clinical and clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. The forward-looking statements contained in this press release are also subject to risks not yet known to Biophytis or not currently considered material by Biophytis. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. These factors include but are not limited to those described under "Risk Factors" in Biophytis’ registration statement relating to the initial public offering. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in the registration statement. We undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by law.

No communication or information relating to the ADS Offering by Biophytis may be transmitted to the public in a country where there is a registration obligation or where an approval is required. The issuance or the subscription of the securities of the Company may be subject to legal and regulatory restrictions in certain jurisdictions; none of Biophytis and the bank involved in the ADS Offering assumes any liability in connection with the breach by any person of such restrictions.

This press release is an advertisement and not a prospectus within the meaning of Directive 2003/71/EC of the European Parliament and the Council of 4 November 2003, as amended or superseded including by Directive 2010/73/EU and as implemented in each member state of the European Economic Area, and of EU Regulation 2017/1129 as supplemented by EU Regulation 2019/980 (the “Prospectus Regulations”).

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to any securities of Biophytis in any country. This press release is not an offer to the public, an offer to subscribe or designed to solicit interest for purposes of an offer to the public in any jurisdiction, including France.

This press release was written in French and English. If there is a difference between the texts, the French version will prevail.

Biophytis Investor Relations Contact

Media Contact

Evelyne Nguyen – CFO

LifeSci Advisors

Evelyne.nguyen@biophytis.com

Sophie Beaumont

sophie@lifesciadvisors.com

Mobile: +33 (0)6 27 74 74 49

Investor Relations

LifeSci Advisors, LLC

Sandya von der Weid

E: svonderweid@lifesciadvisors.com

T: +41 78 680 05 38

PDF: http://ml.globenewswire.com/Resource/Download/23ed1925-d4e3-4e19-9b34-d87c7e9934ab